Downloads: 10 | Views: 181 | Weekly Hits: ⮙4 | Monthly Hits: ⮙4
Review Papers | Pharmaceutical Science | India | Volume 12 Issue 8, August 2023 | Rating: 5.7 / 10
Clinical Accent and Outcomes of the Guillain - Barre Syndrome (Acute Inflammatory Demyelinating Polyradiculoneuropathy)
Shashank Patel | Anupama Singh [3] | Vipin Kesharwani | Pranki Shukla
Abstract: A polyradiculoneuropathy autoimmune disease called Guillain - Barr? syndrome (GBS) is characterized by severe inflammation that damages the peripheral nervous system in a manner that progresses quickly and is primarily seen clinically as muscle weakness. At least 18 of the nation's 24 departments and one constitutional province have recorded at least one incidence of Guillain - Barre Syndrome, according to government records. In response to the unprecedented rise in Guillain - Barre Syndrome, Peruvian authorities announced a 90 - Days nationwide sanitary emergency on July 11, 2023. GBS is now the most frequent cause of acute flaccid paralysis in affluent nations. GBS is still a serious condition despite better detection and care. Anti - GM1 and anti - GQ1B antibodies have been identified as those that attack and harm peripheral neurons or neuromuscular junctions, respectively. Prior research has suggested that the gastrointestinal infection - causing bacteria Campylobacter jejuni predisposes patients to developing GBS. There are multiple subtypes of GBS, but only four of them, acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor, require distinct treatments. Because the subtypes of sensory axonal neuropathy (AMSAN) and Miller - Fisher Syndrome (MFS) differ in their severity and course of treatment. This review seeks to help healthcare professionals better understand GBS and to spread a safety message about the disease.
Keywords: Guillain - Barre syndrome, Campylobacter jejuni, Polyradiculoneuropathy, Plasmapheresis
Edition: Volume 12 Issue 8, August 2023,
Pages: 1019 - 1025